<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR11">
 <label>11.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yu</surname>
    <given-names>HA</given-names>
   </name>
   <name>
    <surname>Sima</surname>
    <given-names>CS</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Solomon</surname>
    <given-names>SB</given-names>
   </name>
   <name>
    <surname>Rimner</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Paik</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Pietanza</surname>
    <given-names>MC</given-names>
   </name>
   <name>
    <surname>Azzoli</surname>
    <given-names>CG</given-names>
   </name>
   <name>
    <surname>Rizvi</surname>
    <given-names>NA</given-names>
   </name>
   <name>
    <surname>Krug</surname>
    <given-names>LM</given-names>
   </name>
   <name>
    <surname>Miller</surname>
    <given-names>VA</given-names>
   </name>
   <name>
    <surname>Kris</surname>
    <given-names>MG</given-names>
   </name>
   <name>
    <surname>Riely</surname>
    <given-names>GJ</given-names>
   </name>
  </person-group>
  <article-title>Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors</article-title>
  <source>J Thorac Oncol</source>
  <year>2013</year>
  <volume>8</volume>
  <issue>3</issue>
  <fpage>346</fpage>
  <lpage>351</lpage>
  <pub-id pub-id-type="doi">10.1097/JTO.0b013e31827e1f83</pub-id>
  <?supplied-pmid 23407558?>
  <pub-id pub-id-type="pmid">23407558</pub-id>
 </element-citation>
</ref>
